Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)

Interventions: Drug: lenalidomide
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine

First Posted Date: 2013-07-22

Last Posted Date: 2018-10-29

Lead Sponsor: Stanford University

Target Recruit Count: 17

Registration Number: NCT01904643

Locations: 🇺🇸
Stanford University, School of Medicine, Stanford, California, United States

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Non-Hodgkin Lymphoma
Acute Leukemia
Hodgkin Lymphoma

Interventions: Drug: Bendamustine
Drug: Clofarabine
Drug: Etoposide
Drug: Etoposide phosphate
Drug: Dexamethasone

First Posted Date: 2013-07-16

Last Posted Date: 2017-03-22

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 16

Registration Number: NCT01900509

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma

Phase 2

Recruiting

Conditions: Seminoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2013-06-26

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 271

Registration Number: NCT01887340

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL

Phase 4

Conditions: Acute Lymphoblastic Leukemia

Interventions: Radiation: TBI
Drug: IDA
Drug: CTX
Drug: VP-16

First Posted Date: 2013-06-10

Last Posted Date: 2015-10-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 100

Registration Number: NCT01873807

Locations: 🇨🇳
Department of Hematology, Union Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳
Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China
🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China

and more 10 locations

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Phase 2

Active, not recruiting

Conditions: Germ Cell Tumors

Interventions: Drug: Paclitaxel
Drug: Ifosfamide
Drug: Bleomycin
Drug: Etoposide
Drug: Cisplatin
Drug: Mesna

First Posted Date: 2013-06-10

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 92

Registration Number: NCT01873326

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 9 locations

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Phase 2

Active, not recruiting

Conditions: Rhabdomyosarcoma

Interventions: Drug: Vincristine
Drug: Dactinomycin
Drug: Cyclophosphamide
Procedure: Surgical Resection
Procedure: Radiation
Drug: Myeloid Growth Factor
Drug: Bevacizumab
Procedure: Lymph Node Sampling
Drug: Sorafenib
Drug: ^1^1C-methionine
Drug: Irinotecan
Drug: Ifosfamide
Drug: Etoposide
Drug: Etoposide Phosphate
Drug: Doxorubicin
Drug: Dexrazoxane

First Posted Date: 2013-06-07

Last Posted Date: 2024-08-09

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 98

Registration Number: NCT01871766

Locations: 🇺🇸
Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸
University of Florida Proton Therapy Institute, Jacksonville, Florida, United States

and more 1 locations

Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Phase 2

Active, not recruiting

Conditions: Newly Diagnosed Ewing Sarcoma

Interventions: Drug: Cyclophosphamide
Device: Doxorubicin
Drug: Vincristine
Drug: Ifosfamide
Drug: Etoposide
Procedure: Surgery
Radiation: Radiation Therapy*
Drug: Temozolomide
Drug: Irinotecan
Drug: Mesna
Drug: Dexrazoxane
Drug: G-CSF

First Posted Date: 2013-05-29

Last Posted Date: 2024-11-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 83

Registration Number: NCT01864109

Locations: 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 4 locations

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Phase 1

Terminated

Conditions: Stage IV Small Cell Lung Cancer

Interventions: Drug: OMP-59R5
Drug: Etoposide
Drug: Placebo
Drug: Cisplatin or Carboplatin

First Posted Date: 2013-05-22

Last Posted Date: 2020-09-09

Lead Sponsor: OncoMed Pharmaceuticals, Inc.

Target Recruit Count: 172

Registration Number: NCT01859741

Locations: 🇺🇸
Univeristy of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Highlands Oncology Group, Rogers, Arkansas, United States

and more 32 locations

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

Phase 2

Conditions: Medulloblastoma

Interventions: Drug: carboplatine
Drug: Etoposide
Radiation: radiation therapy

First Posted Date: 2013-05-20

Last Posted Date: 2018-07-05

Lead Sponsor: Central Hospital, Nancy, France

Target Recruit Count: 97

Registration Number: NCT01857453

Locations: 🇫🇷
Chu Amiens, Amiens, France
🇫🇷
Chu Bordeaux, Bordeaux, France
🇫🇷
CHU CAEN, Caen, France

and more 17 locations

Therapy for Children With Advanced Stage Neuroblastoma

Phase 2

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: cyclophosphamide
Drug: topotecan
Biological: hu14.18K322A
Procedure: peripheral blood stem cell harvest
Procedure: surgical resection
Drug: cisplatin
Drug: etoposide
Drug: doxorubicin
Drug: vincristine
Drug: busulfan
Drug: melphalan
Biological: peripheral blood stem cell transplantation
Biological: natural killer cell infusion
Radiation: radiation therapy
Biological: GM-CSF
Biological: G-CSF
Drug: mesna
Drug: levetiracetam
Biological: interleukin-2
Drug: Isotretinoin
Device: CliniMACS

First Posted Date: 2013-05-20

Last Posted Date: 2024-12-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 153

Registration Number: NCT01857934

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy